Regulation of ligand and shear stress-induced insulin-like growth factor 1 (IGF1) signaling by the integrin pathway
Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts)
The litigation began following publication of a study in July 2024 linking GLP-1 use to non-arteritic anterior ischemic optic neuropathy (NAION), a condition caused by a lack of sufficient blood flow to the optic nerve
However, the levels of Carboxy-HGB varied inconsistently, resulting in a significant interaction
People Taking Retatrutide Lost Weight Rapidly for Some, Too Rapidly More people taking retatrutide quit the study early (called dropping out) compared with those taking placebo: about 12 percent of those taking the lower dose and 18 percent taking the higher dose, compared with 4 percent taking placebo
As emerging evidence builds, providers must balance potential benefits with safety concerns and patient-specific factors
